Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.

Rau T, Wohlleben G, Wuttke H, Thuerauf N, Lunkenheimer J, Lanczik M, Eschenhagen T.

Clin Pharmacol Ther. 2004 May;75(5):386-93.

PMID:
15116051
2.

Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant?

D'Empaire I, Guico-Pabia CJ, Preskorn SH.

J Psychiatr Pract. 2011 Sep;17(5):330-9. doi: 10.1097/01.pra.0000405363.95881.01. Review.

PMID:
21926528
3.

Pharmacogenetics of antidepressants: clinical aspects.

Bertilsson L, Dahl ML, Tybring G.

Acta Psychiatr Scand Suppl. 1997;391:14-21. Review.

PMID:
9265947
4.

[Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].

Szewczuk-Bogusławska M, Grzesiak M, Beszłej JA, Kiejna A.

Psychiatr Pol. 2004 Nov-Dec;38(6):1093-104. Review. Polish.

PMID:
15779673
5.
6.

The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.

Thuerauf N, Lunkenheimer J.

Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):287-93. Review.

PMID:
16783493
7.

Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6.

Kitada M.

Int J Clin Pharmacol Res. 2003;23(1):31-5. Review.

PMID:
14621071
8.

Antidepressant drugs in the elderly--role of the cytochrome P450 2D6.

Vandel P.

World J Biol Psychiatry. 2003 Apr;4(2):74-80. Review.

PMID:
12692778
9.

Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics.

Cacabelos R, Llovo R, Fraile C, Fernández-Novoa L.

Curr Alzheimer Res. 2007 Sep;4(4):479-500. Review.

PMID:
17908053
10.

Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication.

Cascorbi I.

Eur J Clin Invest. 2003 Nov;33 Suppl 2:17-22. Review.

PMID:
14641552
11.

Complexities of CYP2D6 gene analysis and interpretation.

Gaedigk A.

Int Rev Psychiatry. 2013 Oct;25(5):534-53. doi: 10.3109/09540261.2013.825581. Review.

PMID:
24151800
12.

CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants.

Haufroid V, Hantson P.

Clin Toxicol (Phila). 2015 Jul;53(6):501-10. doi: 10.3109/15563650.2015.1049355. Epub 2015 May 22. Review. Erratum in: Clin Toxicol (Phila). 2015 Jul;53(6). doi:10.3109/15563650.2015.1059025.

PMID:
25998998
13.

Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.

Bertilsson L, Dahl ML, Dalén P, Al-Shurbaji A.

Br J Clin Pharmacol. 2002 Feb;53(2):111-22. Review.

14.

Genotyping of cytochrome P450 2D6*3 and *4 mutations using conventional PCR.

Schur BC, Bjerke J, Nuwayhid N, Wong SH.

Clin Chim Acta. 2001 Jun;308(1-2):25-31. Review.

PMID:
11412814
15.

Recent examples on the clinical relevance of the CYP2D6 polymorphism and endogenous functionality of CYP2D6.

Haertter S.

Drug Metabol Drug Interact. 2013;28(4):209-16. doi: 10.1515/dmdi-2013-0032. Review.

PMID:
24088607
16.

[Pharmacokinetics of second generation antidepressants].

Grzesiak M, Beszłej JA, Kiejna A.

Psychiatr Pol. 2000 Jul-Aug;34(4):577-94. Review. Polish.

PMID:
11059258
17.

Strategies to find new genes involved in drug metabolism.

Sheffield LJ.

Curr Opin Mol Ther. 2001 Dec;3(6):579-84. Review.

PMID:
11804272
18.

Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment.

Ingelman-Sundberg M, Oscarson M, McLellan RA.

Trends Pharmacol Sci. 1999 Aug;20(8):342-9. Review.

PMID:
10431214
19.
20.

Clinical Utility and Economic Impact of CYP2D6 Genotyping.

Reynolds KK, McNally BA, Linder MW.

Clin Lab Med. 2016 Sep;36(3):525-42. doi: 10.1016/j.cll.2016.05.008. Epub 2016 Jun 24. Review.

PMID:
27514466

Supplemental Content

Support Center